Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Duality Biotherapeutics, Inc. ( (HK:9606) ) has shared an update.
Duality Biotherapeutics, Inc. has announced a proposal to issue ordinary shares in Renminbi to be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. This proposed issuance is contingent upon market conditions, board and shareholder approvals, and necessary regulatory clearances. The company has not yet made any regulatory applications, and the proposal may be subject to change, with no assurance of proceeding.
The most recent analyst rating on (HK:9606) stock is a Hold with a HK$332.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. operates in the biotherapeutics industry, focusing on the development and commercialization of innovative therapies. The company is incorporated under the laws of the Cayman Islands and is listed on the Stock Exchange of Hong Kong.
Average Trading Volume: 845,279
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$28.17B
For detailed information about 9606 stock, go to TipRanks’ Stock Analysis page.